Join to View Full Profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-648-3571
Fax+1 214-456-8990
Dr. Bhatia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Topiwala National Medical CollegeClass of 2005
Medical University of South CarolinaResidency, Child Neurology- Medical University of South CarolinaFellowship, Epilepsy
Certifications & Licensure
AZ State Medical License 2023 - 2027
CA State Medical License 2024 - 2027
CO State Medical License 2023 - 2027
GA State Medical License 2023 - 2027
MO State Medical License 2026 - 2027
NJ State Medical License 2023 - 2027
NV State Medical License 2025 - 2027
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology- American Board of Psychiatry and Neurology Epilepsy
- Join now to see all
Publications & Presentations
PubMed
- Biomarker discovery in Lennox-Gastaut syndrome: Advances and challenges in electrophysiological, genetic, neuroimaging, and neuroinflammatory approaches.Debopam Samanta, Cemal Karakas, Anthony L Fine, Amanda W Pong, Hyun Yong Koh
Epilepsy & Behavior. 2026-03-01 - Successful IV Thrombolysis in an Adolescent with Postextracorporeal Membrane Oxygenation (ECMO) Cerebral Ischemic Infarct.Hamid Ali, Barbra Giourgas, Sonal Bhatia
Neurology India. 2026-01-01 - 3 citationsRebuilding the Tower of Babel: The Current Landscape and Emerging Opportunities in DEE-SWAS.Robert C Stowe, Sarah A Kelley, Sonal Bhatia, John R McLaren, Lekha M Rao
Epilepsy Currents. 2025-12-01
Press Mentions
- Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual MeetingNovember 3rd, 2023
- Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia BApril 30th, 2024
- FDA Approves CDx to Determine Gene Therapy Eligibility for Hemophilia B PatientsApril 30th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
